002793 罗欣药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-3.733-23.425-32.4089.6378.306
总资产报酬率 ROA (%)-1.711-9.990-13.9074.7164.246
投入资产回报率 ROIC (%)-2.056-11.791-16.8026.0425.693

边际利润分析
销售毛利率 (%)40.20246.27826.74150.19053.637
营业利润率 (%)-9.449-24.810-40.6677.3606.957
息税前利润/营业总收入 (%)-6.492-22.876-37.4638.9677.309
净利润/营业总收入 (%)-9.640-32.528-35.0466.5095.593

收益指标分析
经营活动净收益/利润总额(%)119.31472.963111.686108.534113.390
价值变动净收益/利润总额(%)6.017-1.902-11.182-0.6710.079
营业外收支净额/利润总额(%)-7.8962.9190.2741.740-4.126

偿债能力分析
流动比率 (X)0.9131.0781.0791.5891.646
速动比率 (X)0.7100.8410.9231.4121.428
资产负债率 (%)55.22649.73259.26550.1330.437
带息债务/全部投入资本 (%)45.08036.20051.35639.43929.693
股东权益/带息债务 (%)113.888163.14987.912147.289230.988
股东权益/负债合计 (%)78.68897.04965.98392.093119.893
利息保障倍数 (X)-2.865-8.536-11.2996.07011.634

营运能力分析
应收账款周转天数 (天)67.933104.563200.819157.074134.628
存货周转天数 (天)116.941161.67095.47675.61388.348